Quick Dispatch:
Your tirzepatide cardiovascular outcomes trial results august 2025 Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cardiovascular outcomes trial results august 2025 Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis ships.
Need Help?
Questions about tirzepatide cardiovascular outcomes trial results august 2025 Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cardiovascular outcomes trial results august 2025 Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis in your area.
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
27.83
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
25.55
Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year SURMOUNT‐1 trial - Hankosky
29.46
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
21.12
Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT
28.78
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
23.29
Tirzepatide Demonstrates Cardioprotective Effects in SURPASS-CVOT Trial
23.92
